Phase 4
Completed N=180
Single Injection Adductor Canal Block vs Catheter for Total Knee Arthroplasty
Source: ClinicalTrials.gov NCT02798835 ↗Enrolled (actual)
180
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcomePrimary: Cumulative 24 Hour Oral Morphine Equivalent Consumption — 111.8; 118; 153 mg
◆ Published Evidence
Established
75citations · ~9 / year
A Randomized Non-Inferiority Trial of Adductor Canal Block for Analgesia After Total Knee Arthroplasty: Single Injection Versus Catheter Technique.
Summary
This study investigates single injection adductor canal block (ACB) with or without intravenous dexamethasone and adductor canal catheter for pain management of total knee arthroplasty. This is a non-inferiority trial seeking to determine whether single injection ACB with dexamethasone is "no worse" than a continuous catheter.
Linked Publications
-
A Randomized Non-Inferiority Trial of Adductor Canal Block for Analgesia After Total Knee Arthroplasty: Single Injection Versus Catheter Technique.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cumulative 24 Hour Oral Morphine Equivalent Consumption |
111.8; 118; 153 | — |
| SECONDARY Cumulative 12 Hour Oral Morphine Equivalent Consumption |
61.5; 49.5; 82 | — |
| SECONDARY Cumulative 48 Hour Oral Morphine Equivalent Consumption |
192.9; 196; 223.5 | — |
| SECONDARY Pain Score |
3; 3; 4; 3; 3; 3 | — |
| SECONDARY Quality of Recovery (QoR-40) |
160.5; 166.5; 167.2 | — |
| SECONDARY Length of Stay |
70.8; 71.5; 71.5 | — |
| SECONDARY Incidence of Participants With Nausea/Vomiting Requiring Anti-emetics |
19; 14; 19; 26; 17; 24 | — |
| SECONDARY Time to First Use of PCA |
4.1; 4.9; 3.8 | — |
Eligibility Criteria
Inclusion Criteria
- Patients over or equal to the age of 18 years old who can understand the study protocol and are able to give consent
- Patients with an American Society of Anaesthesiology (ASA) classification 1 to 3
- Patients must have a preoperative oral 24 hour opioid consumption of less than or equal to 30 mg morphine equivalents
- Patients must be able to understand and be able to use patient controlled analgesia
- Patients must be undergoing a primary total knee arthroplasty with neuraxial anesthesia
Exclusion Criteria
- Patients with a contraindication to neuraxial and/or regional anaesthesia
- Patients with an allergy to local anaesthetics
- Patients who have chronic pain not related to their knee joint
- Patients with chronic opioid use (daily or almost daily use >3 months)
- Patients with contraindications to dexamethasone (allergy, infection, Insulin dependent Diabetes Mellitus)
- Patients with pre-existing neuropathy
- Patients with hepatic failure
- Patients with renal failure with eGFR<60
- Patients with allergy to ketorolac or NSAIDs
Data sourced from ClinicalTrials.gov (NCT02798835) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.